Meningitis B Vaccine

A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged 10 To <19 Years.

Register Today!

Trial Information

Trial Duration12 months
Number of Visits6
Lead CRCJessica Richer

For additional information
on this trial contact: